APOMAB

USPTO USPTO 2005 SECTION 71 ACCEPTED

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The US trademark APOMAB was filed as Word mark on 05/05/2005 at the U.S. Patent and Trademark Office.
It was registered as a trademark on 12/18/2007. The current status of the mark is "SECTION 71 ACCEPTED".

Trademark Details

Trademark form Word mark
File reference 79018255
Register number 3356510
Application date May 5, 2005
Publication date October 2, 2007
Entry date December 18, 2007

Trademark owner

Underdale SA 5032

Trademark representatives

goods and services

5 Pharmaceutical products and preparations of antibodies, immunoreactive and/or antigen-binding fragments of antibodies, or direct modifications, conjugates or functionalized derivatives of antibodies, for health care, all the foregoing for the treatment of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia; pharmaceutical products and preparations of antibodies, immunoreactive and/or antigen-binding fragments of antibodies, or direct modifications, conjugates or functionalized derivatives of antibodies, for radio-immuno-diagnosis or radio-immuno-therapy, the foregoing for the diagnosis and treatment of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia; pharmaceutical preparations used in the therapy and diagnosis of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia; diagnostic preparations for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia in humans, the foregoing for medical use; monoclonal antibodies and fragments thereof for cancer research and pharmaceutical development, biomedical research, [ veterinary vaccines, ]veterinary diagnostic and treatment purposes, clinical trials for cancer pharmaceuticals, cancer diagnosis and cancer therapy purposes; cultures and preparations of hybridoma and other cells for medical, diagnostic and veterinary purposes; medicinal products of antibodies, immunoreactive and/or antigen-binding fragments of antibodies, or direct modifications, conjugates or functionalized derivatives of antibodies, the foregoing for the treatment of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia

ID: 1379018255